Presentation of New Biomarker Data at Scientific Congress
Study Results Successfully Inform the Design of ATH434 Phase 2 Clinical Trial Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity”
Read More
We exist to create an alternate future for people with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory for people living with these debilitating diseases.
First-in-class therapies to treat neurodegenerative disease
Alterity is developing first-in-class therapies to treat neurodegenerative disease. Our lead drug candidate, ATH434, has demonstrated efficacy in several animal models of Parkinsonian disorders and is being evaluated in clinical trials.
News
Alterity Announces New US Patent to Expand its Portfolio of Compounds for Neurodegenerative Diseases including Alzheimer’s and Parkinson’s
Composition of Matter Patent Covers More than 80 Novel Compounds Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Co
Read MoreReceive news from Alterity Therapeutics
